samedan logo

 
 
spacer
home > ebr > summer 2019 > fighting the global threat
PUBLICATIONS
European Biopharmaceutical Review

Fighting the Global Threat

The discovery of penicillin by Alexander Fleming in 1928 revolutionised medicine. This antibiotic soon became one of the most widely used in treating common bacterial infections, as well as pneumonia, tuberculosis, syphilis, and more (1). However, the Nobel Prize winner also predicted how an irresponsible use of penicillin could lead to the development of resistant bacteria, resulting in losing the antibiotic efficacy and death caused by a lack of alternative treatments. His concern has become a real-life scenario, affecting the medical sector and animal husbandry on a global scale.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Adrian Fellows has been involved in R&D − particularly in the fields of disinfection and infection control − since 1972. He has filed numerous successful patents in these areas and others, including thermal devices and chemical specialities. Adrian filed the first patent applications for disinfectant wipes in the early 1970s, led a multinational team in an EU framework R&D program, and was a visiting research fellow at Huddersfield University, UK. Since 2005, he has been R&D director for Gama Healthcare, which has become a leading presence in global infection control. More recently, Adrian has been involved in leading collaborative projects in developing novel means to combat AMR.
spacer
Adrian Fellows
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Unlearn Signs Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany to Accelerate Immunology Trials using Twintelligent RCTs™

San Francisco, Calif. – February 16, 2022 – Unlearn®, developer of the Twintelligent RCT™, today announced that the company has entered into a multi-year collaboration with Merck KGaA, Darmstadt, Germany to accelerate late-stage clinical trials with novel trial designs that include Digital Twins. Initially, the collaboration will focus on advancing the regulatory approval of candidates in Merck KGaA, Darmstadt, Germany’s immunology pipeline, with the potential to expand into other therapeutic areas.
More info >>

White Papers

Key to Outsourcing Method Development and Validation A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement